Moreover, our data support the preclinical use of GEMMs to identify cellular and molecular vulnerabilities, and encourage development of future Unesbulin-based therapies that may be tested in the notable percentage of patients with NSCLC carrying EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.